Instil Bio, Inc.
NASDAQ:TILBiotechnology
Healthcare
$7.45 +0.13%
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
52W Low $5.67High $33.83
Volume 0.02M
Average 0.03M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$52.91M
FY 2025 · Annual
Net Income
-$71.37M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 5.99M | 0 | 0 | 534K |
| Gross Profit | 0 | (5.99M) | 0 | 0 | (534K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 107.25M | 141.06M | 39.6M | 11.84M | 10M |
| Selling, General & Admin | 51.31M | 62.24M | 47.55M | 44.21M | 27.22M |
| Operating Expenses | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| EBITDA | (152.51M) | (217.38M) | (147.12M) | (62.53M) | (65.01M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (155.56M) | (206.17M) | (159.17M) | (73.54M) | (52.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 80K | 3.66M | 8.87M | 6.99M | 3.86M |
| Interest Expense | 0 | 1.88M | 5.21M | 8.99M | 5.83M |
| Other Income / Expenses | (1.2M) | (19.08M) | 3.08M | (594K) | (18.47M) |
| Income Before Tax | (156.76M) | (225.25M) | (156.09M) | (74.14M) | (71.37M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39K | (2.07M) | 0 | 0 | 0 |
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| EPS (Diluted) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| 5.3M | 6.48M | 6.5M | 6.51M | 6.67M | |
| 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
TIL Earnings Waterfall · TTM
NASDAQ:TIL · Revenue to Net Income
Key Ratios
EPS$-7.08
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$47.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-7.08, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 |
How much revenue does TIL generate?
Instil Bio, Inc. (TIL) reported $0.00 of revenue in fiscal 2025.
Is TIL profitable?
Instil Bio, Inc. (TIL) reported -$71.37M of net income.
Continue the stock analysis
Jump to another research area for this company.